Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 14/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 12/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2635804 | 0.91 | HCRTR1 (0.48) | HCRTR1HCRTR2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2056850 | 0.84 | HCRTR1 (0.40) | HCRTR1HCRTR2PTGS2 | |
| SCHEMBL2056988 | 0.83 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL2056940 | 0.82 | HCRTR1 (0.40) | HCRTR1HCRTR2RAB9ASMN1; SMN2 | |
| SCHEMBL2056910 | 0.81 | HCRTR1 (0.44) | HCRTR1HCRTR2SMN1; SMN2 | |
| SCHEMBL2056966 | 0.81 | HCRTR1 (0.43) | HCRTR1HCRTR2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3348271 | 0.80 | HCRTR1 (0.40) | HCRTR1HCRTR2PTGS2 | |
| SCHEMBL3415462 | 0.77 | HCRTR1 (0.40) | HCRTR1HCRTR2PTGS2 | |
| SCHEMBL4761846 | 0.76 | PTGS2 (0.54) | PTGS2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2056960 | 0.75 | HCRTR1 (0.47) | HCRTR1HCRTR2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105491-A1 | THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-05-05 | — | — | US | claimed |
| WO-2010004507-A1 | THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-01-14 | — | — | WO | claimed |
| US-20110105491-A1 | THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-05-05 | — | — | US | disclosed |
| WO-2010004507-A1 | THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105491-A1 | THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885PTGS2 2541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.